- Home
- NLOP vs SRDX Comparison
NLOP vs SRDX Comparison
Compare NLOP & SRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLOP
- SRDX
- Stock Information
- Founded
- NLOP 2022
- SRDX 1979
- Country
- NLOP United States
- SRDX United States
- Employees
- NLOP N/A
- SRDX N/A
- Industry
- NLOP
- SRDX Medical/Dental Instruments
- Sector
- NLOP
- SRDX Health Care
- Exchange
- NLOP Nasdaq
- SRDX Nasdaq
- Market Cap
- NLOP 481.5M
- SRDX 562.6M
- IPO Year
- NLOP N/A
- SRDX 1998
- Fundamental
- Price
- NLOP $32.52
- SRDX $39.95
- Analyst Decision
- NLOP Strong Buy
- SRDX Hold
- Analyst Count
- NLOP 1
- SRDX 4
- Target Price
- NLOP $46.00
- SRDX $43.00
- AVG Volume (30 Days)
- NLOP 60.7K
- SRDX 171.3K
- Earning Date
- NLOP 01-01-0001
- SRDX 01-30-2025
- Dividend Yield
- NLOP 1.05%
- SRDX N/A
- EPS Growth
- NLOP N/A
- SRDX N/A
- EPS
- NLOP N/A
- SRDX N/A
- Revenue
- NLOP $160,911,000.00
- SRDX $126,078,000.00
- Revenue This Year
- NLOP N/A
- SRDX $13.75
- Revenue Next Year
- NLOP N/A
- SRDX $13.67
- P/E Ratio
- NLOP N/A
- SRDX N/A
- Revenue Growth
- NLOP N/A
- SRDX N/A
- 52 Week Low
- NLOP $16.04
- SRDX $25.17
- 52 Week High
- NLOP $33.06
- SRDX $42.44
- Technical
- Relative Strength Index (RSI)
- NLOP 58.15
- SRDX 62.80
- Support Level
- NLOP $31.75
- SRDX $39.59
- Resistance Level
- NLOP $32.85
- SRDX $40.39
- Average True Range (ATR)
- NLOP 0.67
- SRDX 0.32
- MACD
- NLOP 0.01
- SRDX -0.03
- Stochastic Oscillator
- NLOP 63.87
- SRDX 59.17
About NLOP Net Lease Office Properties of Beneficial Interest
Net Lease Office Properties is a real estate investment trust. Through its subsidiaries it owns, operates, and finances office buildings. Its properties are primarily leased to corporate tenants on a single-tenant, net-lease basis. Its portfolio includes approximately 1.5 million square feet of Green-Certified Buildings, 4 LEED-Certified Buildings, and 1 BREEAM-Certified Building.
About SRDX Surmodics Inc.
Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The company's mission is to improve the treatment and detection of disease by using its technology to provide solutions to difficult medical devices and diagnostic challenges. It has two reportable segments: Medical device unit; Manufacture of performance coatings, including surface modification coating technologies and the Vitro diagnostics unit; Manufacture of chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets. Surmodics derives majority of its revenue from the Medical Device segment.